← FDA DRUG APPROVALS

FDA NDA · NDA017796

BRYREL

Sponsor: SANOFI AVENTIS US

APPLICATION
NDA017796
TYPE
NDA
ROUTE
ORAL
DOSAGE FORM
SYRUP
MARKETING STATUS
Discontinued

Products

BRYRELDiscontinued
PIPERAZINE CITRATE EQ 500MG BASE/5ML · SYRUP · ORAL
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →